06 September 2018
GoPath Laboratories, IntegraGen’s North American licensing partner for the company’s miR-31-3p test, announced that the American Medical Association (AMA) has assigned a new, discreet CPT (Current Procedural Technology) code to facilitate reimbursement of miR-31now®, a proprietary miRNA-based molecular test which predicts the potential clinical benefits associated with (…) »
04 September 2018
IntegraGen announces the publication of the results of a definitive study reporting on the analysis of the expression of miR-31-3p in tumors from 370 RAS wild-type (WT) metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 clinical trial (AIO KRK-0306). The paper, entitled “Validation of miR-31-3p Expression Level to Predict (…) »
31 July 2018
IntegraGen has announced that it has been selected by the Sequencing Omics Information Analysis (SeqOIA) Cooperative Health Group (GCS) for the operation of its high throughput sequencing platform. The SeqOIA GCS, which includes the Assistance Publique- Hôpitaux de Paris, the Institut Curie and the Gustave Roussy Cancer Center, (…) »
01 June 2018
GoPath Laboratories, IntegraGen’s licensing partner in the U.S., has announced that it will launch a propriety new test, miR-31now™ during the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 1-5, 2018 in Chicago. The miR-31now test is the first positive theranostic test for patients with (…) »
25 May 2018
IntegraGen will be in attendance at 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago from June 1st to June 5th. The Annual ASCO Meeting brings together more than 32,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new (…) »
23 April 2018
IntegraGen announced that it has earned ISO 13485:2016 certification from Bureau Veritas. This certification indicates that the company’s quality management systems meet the specific standards required for the design, development, production and marketing of in vitro diagnostic kits, and lays the foundation for a continuous improvement process for in (…) »
13 April 2018
IntegraGen has announced the company’s financial results for the year ending December 31, 2017. The annual accounts were approved by the Board of Directors held on April 12, 2018.
Click here to view press release.
12 April 2018
IntegraGen announced that it presented data on several proprietary microRNA biomarkers during the 2018 European Lung Cancer Conference (ELCC) being held in Geneva, Switzerland. Based on an analysis of liquid biopsy samples from 133 patients with advanced squamous cell carcinoma of the lung enrolled in the Lux-Lung 8 Phase III (…) »
17 March 2018
IntegraGen is pleased to announce that a comprehensive summary of the results of validation studies associated with the company’s proprietary miR-31-3p expression test has been published online in Biomarker Insights following peer-review.
The paper entitled “Technical validation of a reverse-transcription quantitative polymerase chain reaction in vitro (…) »
14 February 2018
IntegraGen announces a global distribution agreement with Twist Bioscience for IntegraGen’s portfolio of genomic data analysis tools. The agreement includes distribution rights for SIRIUS™, an online Big Data solution that assists researchers to quickly and intuitively analyze exome data for Mendelian and oncology applications, and MERCURY™, an online (…) »